Quantcast

Industry news that matters to you.  Learn more

PerkinElmer Launches Automated Workstation for Improved Process Development of Protein Therapeutics

PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment announced the launch of the JANUS® BioTx ProTM automated workstation for improved process development of protein therapeutics at the 12th Annual Protein Science Week (PepTalk), January 21–25 in Palm Springs, Florida at booth #312. Designed for high throughput, small scale protein purification, it is the only workstation that accommodates multiple chromatography modes (column, tip and batch) eliminating the need for multiple instruments, resulting in more efficient and cost effective sample processing.

Combination of Imaging Exams Improves Alzheimer’s Diagnosis

A combination of diagnostic tests, including imaging and cerebrospinal fluid biomarkers can improve prediction of conversion from mild cognitive impairment (MCI) to Alzheimer’s disease, according to a new study published online in the journal Radiology.

Caris Life Sciences Selects Illumina’s MiSeq® System to Enable Next-Generation Sequencing as Part of its Molecular Profiling Service

Illumina, Inc. (NASDAQ:ILMN) announced last week that Caris Life Sciences has selected its MiSeq sequencing system to support Caris’ evidence-based molecular profiling service. The MiSeq system will be deployed to enable rapid, simultaneous analysis of multiple genes from formalin-fixed, paraffin-embedded (FFPE) tumor tissues using Illumina’s amplicon-based assay.

Biomarkers for Autism Discovered

An important step towards developing a rapid, inexpensive diagnostic method for autism has been take by Uppsala University, among other universities. Through advanced mass spectrometry the researchers managed to capture promising biomarkers from a tiny blood sample. The study has just been published in the prestigious journal Nature Translational Psychiatry.

Detecting Breast Cancer’s Fingerprint in a Droplet of Blood

One in eight women will be diagnosed with breast cancer during her lifetime. The earlier cancer is detected, the better the chance of successful treatment and long-term survival. However, early cancer diagnosis is still challenging as testing by mammography remains cumbersome, costly, and in many cases, cancer can only be detected at an advanced stage. A team based in the Dept. of Biomedical Engineering at McGill University’s Faculty of Medicine has developed a new microfluidics-based microarray that could one day radically change how and when cancer is diagnosed. Their findings are published in the April issue of the journal Molecular & Cellular Proteomics.